

Ms. AnnMarie Miller

64 Haines Street
Lockport, New York 14094

5584 '01 MAR 21

P5.50

U.S. Food & Drug Adm.
Dockets Management Branch
5630 Fishers Lane
Room 1061; HFA-305
Rockville, MD 20852

March 14, 2001

RE: Docket Number **00N-0989**

Dear Sir or Madam:

This proposal (**00N-0989**) only brings gene therapy and xenotransplantation in compliance with the same types of information already released to the public by other government agencies. Because of grave public health risks, disclosure should include additional information such as physicians, medical centers, and so on --- make public all information except trade secrets and patient identification.

The FDA must assume the sole responsibility for summarizing and distributing information submitted by the research sponsor, rather than leave it to sponsors' discretion.

Because of the public health risks, ethical issues, cost uncertainty, and the inability to adequately assess other alternatives, all xenotransplantation clinical trials should stop.

Sincerely,

AnnMarie Miller

AnnMarie Miller

00N-0989

C32